MinaPharm Approves Up to €13.25 Million Loan from EBRD to Support Refinancing and Expansion Plans
The Board of Directors of MinaPharm Pharmaceuticals has approved a financing offer from the European Bank for Reconstruction and Development (EBRD) to provide the company with a loan of up to €13.25 million.
According to a disclosure filed with the Egyptian Exchange (EGX), the facility will be used to refinance a portion of the company’s short- and medium-term loans, which were previously allocated to capital expenditures, product development initiatives, and the establishment of new manufacturing facilities. The financing will also partially support the development of a new professional training academy.
The Board approved all terms, conditions, guarantees, and related documentation associated with the loan, including amendment agreements, drawdown notices, undertakings, certificates, and all other relevant financing documents.
In addition, the Board authorized the Chairman and Managing Director, or the Managing Director — jointly or individually — to sign the loan agreements and all related documents, and to complete all necessary procedures to ensure the facility becomes effective, while maintaining the existing authorities stated in the company’s commercial register without amendment.
It is worth noting that MinaPharm Pharmaceuticals and Chemical Industries reported a 15.5% decline in net profits during the first nine months of 2025, reaching EGP 61.8 million, compared to EGP 73.1 million recorded during the same period of the previous year.